Clinical Trials Logo

Clinical Trial Summary

This study will test the effectiveness of the drug capsaicin in controlling pain after third molar (wisdom tooth) extraction. Capsaicin, the ingredient in chili peppers that makes them "hot," belongs to a class of drugs called vanilloids, which have been found to temporarily inactivate pain-sensing nerves.

Healthy normal volunteers between 16 and 40 years of age who require third molar (wisdom tooth) extraction may be eligible for this study. Participants will undergo the following procedures in three visits:

Visit 1:

Patients will have touch (sensory) testing by the following three methods: 1) a warm sensor applied to the gums and the patient will rate when they first feel heat and when the heat feels painful; 2) the bristles of a small paint brush will be gently stroked across the gums, and the patient will say whether it feels painful; 3) a light touch will be applied to the gums with a small needle, and the patient will rate the pain intensity following the touch.

After testing, patients will be numbed with a local anesthetic (bupivacaine) and then capsaicin or placebo (an inactive solution) will be injected next to the tooth. The tooth then will be extracted one day later.

Visit 2:

Patients will return to the clinic after 24 hours to repeat the same type of sensory testing. After testing, patients will be sedated and numbed with a local anesthetic (lidocaine) and given an intravenous injection of either saline or ketorolac (30 mg). After the extraction, pain ratings will be recorded every 20 minutes, for up to 6 hours. During this time, patients will be monitored for numbness, pain, side effects and vital signs (heart rate, blood pressure, respiration, etc.). Those who request pain medicine will receive acetaminophen and codeine. Patients will be required to stay for up to 3 more hours after this and then they will then be discharged with pain medicine.

Visit 3:

Patients will return to the clinic after another 48 hours to repeat the same sensory testing. Remaining wisdom teeth will be removed "off-study" at least three weeks following the first visit.


Clinical Trial Description

Successful preemptive analgesia strategies are superior to traditional pain management schemes in the management of post-operative pain. However, agents with appropriate pharmacokinetic properties are not readily available. The premise of this double-blind, placebo and positive-controlled clinical study is to evaluate the efficacy of vanilloid agonists as preemptive agents in an oral surgery tissue injury model. Vanilloids are a class of small organic compounds; the most familiar of which is capsaicin, the active ingredient in hot pepper. Binding of capsaicin to the vanilloid-1 receptor produces initial activation and then long-acting desensitization of pain specific neurons. We propose to produce a selective, long-term inactivation of peripheral pain transmission through the local application of capsaicin in the oral mucosa in an effort to prevent or reduce post-operative pain in the oral surgery model. Healthy subjects will be recruited, and following local anesthesia, will be given an intramucosal injection of either capsaicin or placebo. (Or as a positive control, 24 hours later, intravenous Toradol). Subjects will have one lower impacted wisdom tooth extracted under local anesthesia and then will rate their pain. The time of analgesic rescue medication request will be noted. A decrease in post-operative pain and decrease in analgesic use will be taken as a positive effect of the vanilloid for decreasing post-operative pain. We anticipate that through the long term blockade of pain specific fibers pre-operatively that there will be a significant attenuation of post-operative pain development following surgery. This has significant implications for reducing pain and suffering, decreasing analgesic use, and reducing post-operative complications following surgery. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00008476
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date January 2001
Completion date January 2004

See also
  Status Clinical Trial Phase
Withdrawn NCT02957097 - Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures Phase 4
Recruiting NCT05615714 - Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) Phase 1/Phase 2
Active, not recruiting NCT01554332 - Motor Cortex Stimulation for Chronic Neuropathic Pain N/A
Terminated NCT01849796 - Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain Phase 2
Completed NCT00462566 - The Efficacy of Motor Cortex Stimulation for Pain Control N/A
Active, not recruiting NCT05147454 - MRI & QST Analysis in Trigeminal Neuralgia and Persistent Idiopathic Facial Pain
Completed NCT04819763 - Physical Exercises for Temporomandibular Disorders N/A
Completed NCT03462290 - Botox Injections for Patients With Persistent Facial Pain Phase 2
Active, not recruiting NCT04779476 - Effectiveness of Alveogyl and Cutanplast Dressing on Postoperative Pain Following Tooth Extraction: A Clinical Trial
Recruiting NCT05479604 - Treatment of Sinus Headache Using a Novel Device That Combines Acoustic Vibration With Oscillating Expiratory Pressure N/A
Active, not recruiting NCT02131714 - Pressure Pain Threshold of Jaw Muscles in TMD Patients Submitted to a Conservative Treatment N/A
Completed NCT05240703 - Stabilization Splint Treatment of TMD N/A
Terminated NCT00122915 - CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain Phase 3
Completed NCT00355160 - Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting N/A
Recruiting NCT04467398 - Incidence of Intravascular (IV) Injection During Trigeminal Nerve Blocks
Completed NCT02021357 - Proprioceptive Treatment for Temporomandibular Dysfunction N/A
Completed NCT03189823 - Long-term Effect of Motor Cortex Stimulation in Patients Suffering From Chronic Neuropathic Pain N/A
Enrolling by invitation NCT06299995 - Phenotype and Burden of a Midfacial Segment Pain
Completed NCT04249427 - Erenumab for Idiosyncratic Facial Pain Phase 4
Completed NCT02729480 - Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain N/A